{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:28:07Z","timestamp":1778509687915,"version":"3.51.4"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["(Grant No. 2020ZX09201-  009)"],"award-info":[{"award-number":["(Grant No. 2020ZX09201-  009)"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cutaneous T-cell lymphomas (CTCLs) comprise a group of heterogeneous diseases involving malignant T cells. The pathogenesis and etiology of CTCL are still unclear, although a large number of genetic and epidemiological studies on CTCL have been conducted. Most CTCLs have an indolent course, making early diagnosis difficult. Once large-cell transformation occurs, CTCL progresses to more aggressive types, resulting in an overall survival of less than five years. Epigenetic drugs, which have shown certain curative effects, have been selected as third-line drugs in patients with relapsing and refractory CTCL. Many studies have also identified epigenetic biomarkers from tissues and peripheral blood of patients with CTCL and suggested that epigenetic changes play a role in malignant transformation and histone deacetylase inhibitor (HDACi) resistance in CTCL. Single-cell sequencing has been applied in CTCL studies, revealing heterogeneity in CTCL malignant T cells. The mechanisms of HDACi resistance have also been described, further facilitating the discovery of novel HDACi targets. Despite the heterogeneity of CTCL disease and its obscure pathogenesis, more epigenetic abnormalities have been gradually discovered recently, which not only enables us to understand CTCL disease further but also improves our understanding of the specific role of epigenetics in the pathogenesis and treatment. In this review, we discuss the recent discoveries concerning the pathological roles of epigenetics and epigenetic therapy in CTCL.<\/jats:p>","DOI":"10.3389\/fonc.2021.663961","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T04:33:08Z","timestamp":1624509188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Ping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25577","article-title":"Mycosis Fungoides and S\u00e9zary Syndrome: 2019 Update on Diagnosis, Risk-Stratification, and Management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00765","article-title":"Update on Biology of Cutaneous T-Cell Lymphoma","volume":"10","author":"Phyo","year":"2020","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 Update of the WHO-EORTC Classification for Primary Cutaneous Lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01558","article-title":"An Update on Molecular Biology of Cutaneous T Cell Lymphoma","volume":"9","author":"Walia","year":"2019","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/1203475415589055","article-title":"Assessment of Tissue Level of Histone Deactylase-2 (Hdac-2) in Patients With Mycosis Fungoides","volume":"20","author":"El Tawdy","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.0309-0167.2008.03109.x","article-title":"Prognostic Significance of the Therapeutic Targets Histone Deacetylase 1, 2, 6 and Acetylated Histone H4 in Cutaneous T-Cell Lymphoma","volume":"53","author":"Marquard","year":"2008","journal-title":"Histopathology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/2159-8290.CD-15-1297","article-title":"Mechanism, Consequences, and Therapeutic Targeting of Abnormal Il15 Signaling in Cutaneous T-Cell Lymphoma","volume":"6","author":"Mishra","year":"2016","journal-title":"Cancer Discovery"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.2.219","article-title":"Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype CD8+ T Cells","volume":"193","author":"Fehniger","year":"2001","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04192.x","article-title":"Interleukin-15 Expression in Cutaneous T-Cell Lymphoma (Mycosis Fungoides and S\u00e9zary Syndrome)","volume":"144","author":"Leroy","year":"2001","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2000.009004248.x","article-title":"Il-15 and IL-16 Overexpression in Cutaneous T-Cell Lymphomas: Stage-Dependent Increase in Mycosis Fungoides Progression","volume":"9","author":"Asadullah","year":"2000","journal-title":"Exp Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11587","article-title":"Selective Inhibition of HDAC6 Sensitizes Cutaneous T-Cell Lymphoma to PI3K Inhibitors","volume":"20","author":"Bobrowicz","year":"2020","journal-title":"Oncol Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0380-7","article-title":"Current Status of HDAC Inhibitors in Cutaneous T-Cell Lymphoma","volume":"19","author":"Lopez","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b01014","article-title":"Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells","volume":"12","author":"Iaconelli","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00706-15","article-title":"Histone Deacetylase 3 Is Required for Efficient T Cell Development","volume":"35","author":"Stengel","year":"2015","journal-title":"Mol Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e68915","DOI":"10.1371\/journal.pone.0068915","article-title":"Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma","volume":"8","author":"Wells","year":"2013","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin as Monotherapy for Patients With Cutaneous T-Cell Lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory Cutaneous T-Cell Lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13222","article-title":"A Phase II Trial of Belinostat (PXD101) in Patients With Relapsed or Refractory Peripheral or Cutaneous T-Cell Lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat Activity in Both Bexarotene-Exposed and -Na\u00efve Patients With Refractory Cutaneous T-Cell Lymphoma: Results of a Phase II Trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.13400","article-title":"Romidepsin in Peripheral and Cutaneous T-Cell Lymphoma: Mechanistic Implications From Clinical and Correlative Data","volume":"170","author":"Bates","year":"2015","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361022","article-title":"Responses to Romidepsin in Patients With Cutaneous T-Cell Lymphoma and Prior Treatment With Systemic Chemotherapy","volume":"59","author":"Duvic","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2691","article-title":"Romidepsin Treatment for Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma: Real-Life Data From a National Multicenter Observational Study","volume":"37","author":"Shimony","year":"2019","journal-title":"Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of Durable Disease Control With Chemotherapy for Mycosis Fungoides and S\u00e9zary Syndrome: A Comparative Study of Systemic Therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0004","article-title":"Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma","volume":"2","author":"Martinez-Escala","year":"2016","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01554.x","article-title":"Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor Vorinostat in Japanese Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma","volume":"39","author":"Wada","year":"2012","journal-title":"J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: A New Oral Histone Deacetylase Inhibitor Approved for Cutaneous T-Cell Lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1886","article-title":"Vorinostat for Refractory or Relapsing Epidermotropic T-Cell Lymphoma: A Retrospective Cohort Study of 15 Patients","volume":"95","author":"Kogge","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.02.980","article-title":"Bcl11b-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma","volume":"137","author":"Fu","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4161\/cc.27523","article-title":"SIRT1 is Upregulated in Cutaneous T-Cell Lymphoma, and its Inhibition Induces Growth Arrest and Apoptosis","volume":"13","author":"Nihal","year":"2014","journal-title":"Cell Cycle"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-017-1761-0","article-title":"Vorinostat and Mithramycin A in Combination Therapy as an Interesting Strategy for the Treatment of S\u00e9zary T Lymphoma: A Transcriptomic Approach","volume":"309","author":"Ragheb","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and Histone Deacetylase Inhibition Against Leukemic Cells From Cutaneous T-Cell Lymphoma Patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0719-4","article-title":"Elucidating the Mechanism of Action of Domatinostat (4SC-202) in Cutaneous T Cell Lymphoma Cells","volume":"12","author":"Wobser","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.19.06503-9","article-title":"Current Status of Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma","volume":"154","author":"Trager","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702518104","article-title":"A Functional Genetic Screen Identifies Retinoic Acid Signaling as a Target of Histone Deacetylase Inhibitors","volume":"104","author":"Epping","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat Combined With Bexarotene for Treatment of Cutaneous T-Cell Lymphoma: In Vitro and Phase I Clinical Evidence Supporting Augmentation of Retinoic Acid Receptor\/Retinoid X Receptor Activation by Histone Deacetylase Inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.12.6","article-title":"HDAC Inhibitors for the Treatment of Cutaneous T-Cell Lymphomas","volume":"4","author":"Rangwala","year":"2012","journal-title":"Future Med Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.889","article-title":"A Novel Regimen of Vorinostat With Interferon Gamma for Refractory S\u00e9zary Syndrome","volume":"61","author":"Gardner","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.043","article-title":"Romidepsin and Interferon Gamma: A Novel Combination for Refractory Cutaneous T-Cell Lymphoma","volume":"68","author":"Samimi","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jdermsci.2015.10.016","article-title":"Combination of Retinoid and Histone Deacetylase Inhibitor Produced an Anti-Tumor Effect in Cutaneous T-Cell Lymphoma by Restoring Tumor Suppressor Gene, Retinoic Acid Receptor\u03b22, Via Histone Acetylation","volume":"81","author":"Kato","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2014.01.009","article-title":"Histone Deacetylase Inhibitors Potentiate Photochemotherapy in Cutaneous T-Cell Lymphoma MyLa Cells","volume":"131","author":"Sung","year":"2014","journal-title":"J Photochem Photobiol B"},{"key":"B45","article-title":"The Efficacy of Vorinostat in Combination With Interferon Alpha and Extracorporeal Photopheresis in Late Stage Mycosis Fungoides and Sezary Syndrome","volume":"10","author":"Sanli","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013870","article-title":"Vorinostat Interferes With the Signaling Transduction Pathway of T-Cell Receptor and Synergizes With Phosphoinositide-3 Kinase Inhibitors in Cutaneous T-Cell Lymphoma","volume":"95","author":"Wozniak","year":"2010","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01239.x","article-title":"Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA With the Proteasome Inhibitor Bortezomib in Cutaneous T Cell Lymphoma","volume":"82","author":"Heider","year":"2009","journal-title":"Eur J Haematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and Azacitidine Synergize in Their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10905.x","article-title":"Low-Dose Electron Beam Radiation and Romidepsin Therapy for Symptomatic Cutaneous T-Cell Lymphoma Lesions","volume":"167","author":"Akilov","year":"2012","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18522","article-title":"A Comparative Analysis of Histone Deacetylase Inhibitors for the Treatment of Mycosis Fungoides and S\u00e9zary Syndrome","volume":"182","author":"Papps","year":"2020","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0109","article-title":"Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for K(ATP) Channel","volume":"19","author":"Noonan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.018","article-title":"Panoptic Clinical Review of the Current and Future Treatment of Relapsed\/Refractory T-Cell Lymphomas: Cutaneous T-Cell Lymphomas","volume":"99","author":"Zinzani","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1014360","article-title":"Clinically Significant Responses Achieved With Romidepsin Across Disease Compartments in Patients With Cutaneous T-Cell Lymphoma","volume":"56","author":"Kim","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab Versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC): An International, Open-Label, Randomised, Controlled Phase 3 Trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","article-title":"Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-Cell Lymphoma","volume":"21","author":"Porcu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0369","article-title":"Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides But Possibly Indicating Durable Clinical Response","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neo.2018.11.006","article-title":"Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma","volume":"21","author":"Zhao","year":"2019","journal-title":"Neoplasia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/cancers12082129","article-title":"Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using Rna-Seq Technologies","volume":"12","author":"Rassek","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective Induction of Apoptosis by Histone Deacetylase Inhibitor SAHA in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action","volume":"125","author":"Zhang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2017.1341487","article-title":"The Discovery and Development of Romidepsin for the Treatment of T-Cell Lymphoma","volume":"12","author":"Smolewski","year":"2017","journal-title":"Expert Opin Drug Discovery"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-24","article-title":"Novel Therapeutic Agents for Cutaneous T-Cell Lymphoma","volume":"5","author":"Jain","year":"2012","journal-title":"J Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0466","article-title":"Atf3 Repression of BCL-X(L) Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types","volume":"23","author":"Ch\u00fceh","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/j.jid.2019.12.041","article-title":"Involvement of P53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition","volume":"140","author":"Yu","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.jid.2019.03.1130","article-title":"Contribution of STAT3 and RAD23B in Primary S\u00e9zary Cells to Histone Deacetylase Inhibitor Fk228 Resistance","volume":"139","author":"Butler","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6091","article-title":"Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma","volume":"68","author":"Fantin","year":"2008","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccr.2008.12.001","article-title":"Genome-Wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis","volume":"15","author":"Fotheringham","year":"2009","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0913912107","article-title":"HR23B is a Biomarker for Tumor Sensitivity to HDAC Inhibitor-Based Therapy","volume":"107","author":"Khan","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.07.053","article-title":"Novel Cell Adhesion\/Migration Pathways are Predictive Markers of HDAC Inhibitor Resistance in Cutaneous T Cell Lymphoma","volume":"46","author":"Andrews","year":"2019","journal-title":"EBioMedicine"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2017.06.008","article-title":"Hdac Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL","volume":"32","author":"Ott","year":"2017","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-449140","article-title":"MAPK Pathway Activation Leads to Bim Loss and Histone Deacetylase Inhibitor Resistance: Rationale to Combine Romidepsin With an MEK Inhibitor","volume":"121","author":"Chakraborty","year":"2013","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","article-title":"Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors","volume":"32","author":"Qu","year":"2017","journal-title":"Cancer Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-18-3309","article-title":"Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated With Disease Progression","volume":"25","author":"Borcherding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-Cell Heterogeneity in S\u00e9zary Syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv"},{"key":"B74","doi-asserted-by":"publisher","first-page":"E491","DOI":"10.1002\/ajh.24564","article-title":"A Retrospective Comparative Outcome Analysis Following Systemic Therapy in Mycosis Fungoides and Sezary Syndrome","volume":"91","author":"Hanel","year":"2016","journal-title":"Am J Hematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2018.07.003","article-title":"Mass Spectrometry and DigiWest Technology Emphasize Protein Acetylation Profile From Quisinostat-Treated Hut78 CTCL Cell Line","volume":"187","author":"M\u00e9hul","year":"2018","journal-title":"J Proteomics"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.05.114","article-title":"Global Patterns of Methylation In\u00a0S\u00e9zary Syndrome Provide Insight Into\u00a0The\u00a0Role of Epigenetics In\u00a0Cutaneous\u00a0T-Cell Lymphoma","volume":"136","author":"Whittaker","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.311","article-title":"Downregulation of SAMHD1 Expression Correlates With Promoter DNA Methylation in S\u00e9zary Syndrome Patients","volume":"134","author":"de Silva","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14108","article-title":"Methylation Patterns of Cutaneous T-Cell Lymphomas","author":"I\u017cykowska","year":"2020","journal-title":"Exp Dermatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.116","article-title":"Promoter-Specific Hypomethylation is Associated With Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome","volume":"135","author":"Wong","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.025","article-title":"Increased Expression of PLS3 Correlates With Better Outcome in S\u00e9zary Syndrome","volume":"137","author":"Boonk","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-845834","article-title":"Aberrant CD137 Ligand Expression Induced by GATA6 Overexpression Promotes Tumor Progression in Cutaneous T-Cell Lymphoma","volume":"132","author":"Kamijo","year":"2018","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15729","article-title":"Hypomethylation of the Promoter Region Drives Ectopic Expression of TMEM244 in S\u00e9zary Cells","volume":"24","author":"I\u017cykowska","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01682.x","article-title":"Frequent Abnormalities of the p15 and p16 Genes in Mycosis Fungoides and Sezary Syndrome","volume":"118","author":"Scarisbrick","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B84","article-title":"Methylation Status of the p15, p16 and MGMT Promoter Genes in Primary Cutaneous T-Cell Lymphomas","volume":"89","author":"Gallardo","year":"2004","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12717","article-title":"A Specific DNA Methylation Profile Correlates With a High Risk of Disease Progression in Stage I Classical (Alibert-Bazin Type) Mycosis Fungoides","volume":"170","author":"Ferrara","year":"2014","journal-title":"Br J Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.353","article-title":"Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and P73","volume":"23","author":"van Doorn","year":"2005","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3574","article-title":"Mycosis Fungoides Shows Concurrent Deregulation of Multiple Genes Involved in the TNF Signaling Pathway: An Expression Profile Study","volume":"102","author":"Tracey","year":"2003","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/35000501","article-title":"Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.301","article-title":"Downregulation of Fas Gene Expression in S\u00e9zary Syndrome Is Associated With Promoter Hypermethylation","volume":"130","author":"Jones","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.309","article-title":"Low FAS\/CD95 Expression by CTCL Correlates With Reduced Sensitivity to Apoptosis That can be Restored by FAS Upregulation","volume":"129","author":"Wu","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1046\/j.1523-1747.2003.12496.x","article-title":"Microsatellite Instability is Associated With Hypermethylation of the hMLH1 Gene and Reduced Gene Expression in Mycosis Fungoides","volume":"121","author":"Scarisbrick","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.042","article-title":"Epigenomic Analysis of S\u00e9zary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic\u00a0Markers","volume":"136","author":"van Doorn","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.05.126","article-title":"Inactivation of RUNX3\/p46 Promotes Cutaneous T-Cell Lymphoma","volume":"136","author":"Haider","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.427","article-title":"Epigenetic Causes of Apoptosis Resistance in Cutaneous T-Cell Lymphomas","volume":"130","author":"Contassot","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-534693","article-title":"SATB1 Overexpression Promotes Malignant T-Cell Proliferation in Cutaneous CD30+ Lymphoproliferative Disease by Repressing P21","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1526","article-title":"SATB1 in Malignant T Cells","volume":"138","author":"Fredholm","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294819","article-title":"Deficiency of SATB1 Expression in Sezary Cells Causes Apoptosis Resistance by Regulating FasL\/CD95L Transcription","volume":"117","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.07.714","article-title":"Low SATB1 Expression Promotes IL-5 and IL-9 Expression in S\u00e9zary Syndrome","volume":"140","author":"Herrera","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.018","article-title":"Satb1 Is a Pivotal Epigenetic Biomarker in Cutaneous T-Cell Lymphomas","volume":"138","author":"Poglio","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135711","article-title":"Methyltransferase Inhibitors Restore SATB1 Protective Activity Against Cutaneous T Cell Lymphoma in Mice","volume":"131","author":"Harro","year":"2021","journal-title":"J Clin Invest"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.05.120","article-title":"Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma","volume":"141","author":"Gao","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3597","article-title":"Expression of Special AT-rich Sequence-Binding Protein 1 Is an Independent Prognostic Factor in Cutaneous T-Cell Lymphoma","volume":"33","author":"Grzanka","year":"2015","journal-title":"Oncol Rep"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/bjd.12870","article-title":"Mycosis Fungoides: Promoter Hypermethylation Predicts Disease Progression","volume":"170","author":"van Doorn","year":"2014","journal-title":"Br J Dermatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-460535","article-title":"Use of PLS3, Twist, CD158k\/KIR3DL2, and NKp46 Gene Expression Combination for Reliable S\u00e9zary Syndrome Diagnosis","volume":"121","author":"Michel","year":"2013","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.038","article-title":"Evaluation of Immunophenotypic and Molecular Biomarkers for S\u00e9zary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients","volume":"136","author":"Boonk","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2813","article-title":"Quantitative PCR on 5 Genes Reliably Identifies CTCL Patients With 5% to 99% Circulating Tumor Cells With 90% Accuracy","volume":"107","author":"Nebozhyn","year":"2006","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09587.x","article-title":"T-Plastin (PLS3) Gene Expression Differentiates S\u00e9zary Syndrome From Mycosis Fungoides and Inflammatory Skin Diseases and can Serve as a Biomarker to Monitor Disease Progression","volume":"162","author":"Tang","year":"2010","journal-title":"Br J Dermatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.106","article-title":"Regulation of T-Plastin Expression by Promoter Hypomethylation in Primary Cutaneous T-Cell Lymphoma","volume":"132","author":"Jones","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3356","article-title":"Genomic Landscape of Cutaneous T Cell Lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001470","article-title":"Primary Cutaneous Cd4+ Small\/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group","volume":"44","author":"Beltzung","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3444","article-title":"Genomic Profiling of S\u00e9zary Syndrome Identifies Alterations of Key T Cell Signaling and Differentiation Genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic Analyses Reveal Recurrent Mutations in Epigenetic Modifiers and the JAK-STAT Pathway in S\u00e9zary Syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3442","article-title":"The Mutational Landscape of Cutaneous T Cell Lymphoma and S\u00e9zary Syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate Driver Genes Involved in Genome Maintenance and DNA Repair in S\u00e9zary Syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic Analysis of 220 CTCLs Identifies a Novel Recurrent Gain-of-Function Alteration in RLTPR (P.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-256719","article-title":"MicroRNA Expression in Sezary Syndrome: Identification, Function, and Diagnostic Potential","volume":"116","author":"Ballabio","year":"2010","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1500","article-title":"Microrna Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma","volume":"138","author":"Shen","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e0224305","DOI":"10.1371\/journal.pone.0224305","article-title":"Potential Role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in Diagnosis and Prediction of Disease Progression in Mycosis Fungoides in Egyptian Patients","volume":"14","author":"Talaat","year":"2019","journal-title":"PloS One"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/ijms18102136","article-title":"Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas","volume":"18","author":"Dus\u00edlkov\u00e1","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788950","article-title":"Prognostic miRNA Classifier in Early-Stage Mycosis Fungoides: Development and Validation in a Danish Nationwide Study","volume":"131","author":"Lindahl","year":"2018","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/cancers12051229","article-title":"MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas","volume":"12","author":"Gluud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14124","article-title":"Suppressed microRNA-195-5p Expression in Mycosis Fungoides Promotes Tumor Cell Proliferation","author":"Rittig","year":"2020","journal-title":"Exp Dermatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2019.1629789","article-title":"miR-337 Suppresses Cutaneous T-Cell Lymphoma Via the STAT3 Pathway","volume":"18","author":"Xia","year":"2019","journal-title":"Cell Cycle"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.328","article-title":"Notch1 Pathway Activation Results From the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides","volume":"135","author":"Gallardo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15036","article-title":"Mapping Signal Transducer and Activator of Transcription (STAT) Activity in Different Stages of Mycosis Fungoides and Sezary Syndrome","volume":"59","author":"Olszewska","year":"2020","journal-title":"Int J Dermatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00403-020-02062-5","article-title":"The Polymorphisms of IL-6\/STAT3 Signaling Pathway may Contribute to Cutaneous T-Cell Lymphomas Susceptibility","volume":"313","author":"Olszewska","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18098","article-title":"Advanced-Stage Mycosis Fungoides: Role of the Signal Transducer and Activator of Transcription 3, Nuclear Factor-\u03bab and Nuclear Factor of Activated T Cells Pathways","volume":"182","author":"P\u00e9rez","year":"2020","journal-title":"Br J Dermatol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/cells9122692","article-title":"Epigenetic Silencing of Tumor Suppressor Mir-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma","volume":"9","author":"Garc\u00eda-Colmenero","year":"2020","journal-title":"Cells"},{"key":"B129","doi-asserted-by":"publisher","first-page":"adv00270","DOI":"10.2340\/00015555-3574","article-title":"Microrna-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides","volume":"100","author":"Lindahl","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.487","article-title":"MicroRNA Expression Profiling and DNA Methylation Signature for Deregulated microRNA in Cutaneous T-Cell Lymphoma","volume":"135","author":"Sandoval","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002049","article-title":"The Synergistic Proapoptotic Effect of PARP-1 and HDAC Inhibition in Cutaneous T-Cell Lymphoma is Mediated Via Blimp-1","volume":"4","author":"Kruglov","year":"2020","journal-title":"Blood Adv"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.05.110","article-title":"Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation Between Inhibitions of PI3K\u03b1\/\u03b4 and HDAC","volume":"141","author":"Wu","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-176024","article-title":"Cotreatment With BCL-2 Antagonist Sensitizes Cutaneous T-Cell Lymphoma to Lethal Action of HDAC7-Nur77-Based Mechanism","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.663961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T04:33:12Z","timestamp":1624509192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.663961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":133,"alternative-id":["10.3389\/fonc.2021.663961"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.663961","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"article-number":"663961"}}